Progout

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Progout

Progout is a synthetic, prescription-only medication primarily used to manage metabolic conditions associated with high uric acid levels. Its active ingredient is Allopurinol, classifying it as a foundational agent in maintenance therapy. It addresses the long-term cause of elevated urate concentrations, acting as a disease-modifying agent rather than a pain reliever, a distinction based on its pharmacological profile.

What Type of Medicine is Progout (Allopurinol)?

Progout is categorized pharmacologically as a Xanthine Oxidase Inhibitor (XOI), a distinct class of medication used to control the overproduction of uric acid. This classification identifies Allopurinol as a purine analogue, a chemically synthesized compound structurally designed to interrupt a specific metabolic process. This compound works within the body to address chronic metabolic imbalance. Its mode of action contrasts with other urate-lowering agents that increase the excretion of uric acid via the kidneys.

Form, Composition, and General Action

Progout is supplied as a tablet, an oral dosage form intended for convenient, systemic administration. The composition features the active substance Allopurinol alongside necessary pharmaceutical excipients. Once absorbed, it performs its primary function: blocking the xanthine oxidase enzyme. This action effectively reduces the total amount of uric acid production in the body, which is the established mechanism for reducing serum urate concentrations. This medicine is characterized by its ability to control uric acid levels at the metabolic source.

The Overall Purpose of Anti-Hyperuricemic Agents

The essential therapeutic purpose of Progout is to achieve and sustain normalized serum urate concentrations, positioning it as a crucial anti-hyperuricemic agent. By consistently controlling the metabolic pathway that generates uric acid, the drug provides foundational stability against the buildup and crystallization of urates in joints and tissues. This metabolic stabilization offers the long-term support necessary to mitigate the risks associated with chronic high urate levels, addressing the underlying cause rather than just alleviating immediate symptoms. A typical use scenario involves initiating treatment in individuals with established chronic hyperuricemia to prevent tissue damage over time.

Regulatory References

  1. Allopurinol Pharmacology (NIH)

What side effects are possible with Progout?

Possible Side Effects and Safety Information

The safety profile of Progout (Allopurinol) is classified by regulatory authorities based on the affected physiological system and frequency of occurrence. All adverse events and safety characteristics are derived from official government-approved prescribing information, maintaining a focus strictly on documented risks.


Classified Adverse Reactions and Systems

Adverse effects are categorized by the System Organ Class (SOC) structure. The most frequent reactions are generally classified as Common, including skin rash, which is the most widely documented effect. Other common findings include nausea, diarrhea, and elevations in liver enzyme levels.

  • Uncommon reactions include generalized hypersensitivity reactions.
  • Rare reactions, such as hepatitis and blood dyscrasias (e.g., leukopenia, thrombocytopenia), are also documented in regulatory sources.

Serious Adverse Reactions

The most critical risk officially highlighted is the development of Severe Cutaneous Adverse Reactions (SCARs), classified as Rare. These systemic skin conditions include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS syndrome. These reactions are formally recognized as being more likely to occur during the initial months of administration.


Population-Specific and Contextual Safety Notes

The official safety profile mandates consideration for specific patient factors. Individuals with renal impairment require lower doses to prevent the drug from accumulating in the system. Furthermore, a genetic risk factor is documented: patients carrying the *HLA-B58:01 allele have an officially recognized increased risk of severe hypersensitivity reactions. An acute gout flare is also noted as a possible event upon the initiation of therapy** due to the drug's effect on urate levels. Contraindication is established for individuals with known hypersensitivity to the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Progout (Allopurinol) by documenting specific clinical manifestations and mandated emergency actions. Suspected overdose requires immediate medical attention to mitigate the risk of severe complications.


Documented Manifestations and Critical Outcomes

Classification Official Regulatory Statement
Documented Presentations Overdose may present with common manifestations including nausea, vomiting, diarrhea, and drowsiness [Source 1.3].
Critical Organ Risks The primary concern is the potential for acute renal failure and hepatic toxicity, which are severe, life-threatening outcomes associated with excessive exposure [Source 1.2].
Population Note Patients with decreased renal function face an increased risk of toxicity following overdose due to impaired clearance of the active metabolite [Source 3.4].

Management and Emergency Actions

Official labeling states that no specific antidote is known for Allopurinol overdose. Management is limited to symptomatic and supportive treatment. For severe cases, haemodialysis is described as a procedural measure to effectively remove the drug and its metabolite from the system. Due to critical risk, close monitoring of renal function is a required component of post-overdose management. The label dictates that patients must seek immediate medical attention upon any suspicion of overdose or if severe symptoms, such as an extensive rash, occur.

Therapeutic Uses of Progout

What Progout treats: main uses and benefits

Progout is a medication primarily used to manage conditions associated with elevated levels of uric acid in the bloodstream. By helping to regulate these levels, the medication assists in preventing the physical complications that arise when excess uric acid forms crystals in the body.

Primary Uses

The most common application of Progout is the long-term management of gout. Gout is a form of inflammatory arthritis characterized by sudden and severe pain, redness, and swelling in the joints. These symptoms are caused by the deposition of urate crystals within the joint space. Progout works to lower the concentration of uric acid, thereby reducing the frequency and severity of gout flares over time.

Beyond gout, the medication is also utilized in the following scenarios:

  • Kidney Stone Prevention: It is used to reduce the formation of certain types of kidney stones, specifically those composed of uric acid or calcium oxalate, by lowering the amount of uric acid excreted in the urine.
  • Chemotherapy Support: Certain medical treatments, such as chemotherapy for cancer, can lead to a rapid breakdown of cells. This process may cause a significant spike in uric acid levels, which can be harmful to the kidneys. Progout is used to manage these levels during such treatments.

Benefits and Long-term Management

The primary benefit of Progout is its ability to maintain uric acid at a stable, healthy level. Unlike medications used to treat acute pain during a gout attack, Progout is a preventative treatment intended for consistent use.

Key benefits of maintaining controlled uric acid levels include:

  • Joint Protection: By preventing the accumulation of crystals, the medication helps protect joints from the chronic damage and deformity that can result from untreated gout.
  • Reduction of Tophi: Over time, consistent treatment can lead to the dissolution of tophi, which are visible, hard deposits of uric acid crystals that form under the skin or around joints.
  • Kidney Health: Lowering uric acid levels in the blood and urine can reduce the physiological stress on the kidneys, helping to prevent stone formation and associated renal complications.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Progout (Allopurinol) — Official Regulatory Information

Eligibility Scope

Classification Status and Population Details (Regulatory Statement)
Populations Allowed Adult Gout Patients, Recurrent Stone Patients, and Cancer-related Hyperuricemia (Adult/Pediatric) Permitted for adults with gout/stones; for hyperuricemia due to malignancy in adult and pediatric populations.
Populations Not Recommended Asymptomatic Hyperuricemia & Acute Gout Attack Not recommended for high uric acid levels alone or to initiate treatment during an acute gout flare.
Populations Contraindicated Severe Hypersensitivity Must not use with a known history of severe allergic reaction to allopurinol.

Age-Related Eligibility Rules

Age Group Eligibility Status
Adults Approved for all stated indications.
Pediatric Population Use is rare and generally only approved for hyperuricemia secondary to malignancy or specific enzyme disorders.

Condition-Specific and Special Population Eligibility

Condition/Status Eligibility Classification
Renal or Hepatic Impairment Conditional Use/Caution Required. Requires regulated dosage adjustment due to drug clearance concerns.
*Genetic Risk (HLA-B58:01)** Restricted Use. Not recommended unless benefits outweigh the high risk of severe hypersensitivity, especially in certain ethnic groups.
Pregnancy/Lactation Conditional/Not Recommended. Pregnancy use is only advised if absolutely required. Lactation is not recommended.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use the medicine by establishing absolute barriers (hypersensitivity) and clear conditional eligibility for populations with organ dysfunction. Use in all other patients, including those with genetic risk factors or specific physiological states (pregnancy/lactation), is defined by a regulatory assessment of necessity or heightened caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Progout (Allopurinol) interacts with certain substances primarily by altering their metabolism, which may increase systemic exposure or toxicity risk, as documented in regulatory labeling.

Formally Restricted Combinations

Co-administration with specific medications is either prohibited or requires mandatory restrictions.

  • Pegloticase: Allopurinol therapy must be discontinued and not initiated during Pegloticase treatment.
  • Capecitabine: Concomitant use with Allopurinol should be avoided.

Clinically Significant Exposure Alterations

Progout’s metabolic inhibition requires significant modifications for co-administered drugs to manage exposure levels.

  • Mercaptopurine / Azathioprine: Co-administration causes a substantial increase in the active metabolite's plasma exposure, requiring a formal dose reduction of the thiopurines.
  • Didanosine / Theophylline: Allopurinol reduces the clearance of these agents, resulting in increased plasma concentrations; monitoring or dose modification of the co-administered drug is necessary.

Pharmacodynamic and Clearance Interactions

Interactions may involve additive risks or competition for elimination:

  • Thiazide Diuretics / ACE Inhibitors: Co-administration is associated with an increased risk of hypersensitivity reactions, with the risk being heightened in patients with decreased renal function.
  • Uricosuric Agents: Substances like Probenecid may increase the clearance of Allopurinol’s active metabolite, oxipurinol, which can reduce the overall therapeutic effect.

Administration Requirements

The label specifies timing rules to manage product effects:

  • Allopurinol should be taken after a meal to reduce the possibility of gastrointestinal irritation and must be separated from Aluminum Hydroxide (antacids) by three hours.

Mechanism of Action

How Progout Works

Progout (allopurinol) exerts its pharmacological effect by acting within domains involving enzyme-mediated signaling in the purine catabolic pathway. Its primary function is the non-competitive inhibition of the enzyme xanthine oxidase (XO).

This inhibition is mediated by both the parent compound, allopurinol, and its long-acting, active metabolite, oxypurinol, which is formed in vivo. Oxypurinol is a potent, time-dependent inhibitor of XO, forming a tightly bound complex with the enzyme's molybdenum-pterin active site.

This interaction interrupts the purine catabolic cascade, specifically suppressing the enzymatic conversion of hypoxanthine to xanthine, and subsequently the conversion of xanthine to uric acid. By modifying these terminal molecular steps, the drug reduces the overall rate of uric acid synthesis throughout the body.

The resulting physiological consequence is a decrease in the concentration of uric acid in both plasma and urine. This reduction modifies the systemic metabolite burden, inducing a shift in the steady-state concentration of purine metabolites.

Dosage and Administration Information

How Progout is Used

Progout (Allopurinol) is administered through two approved routes: oral (tablet form) for long-term management and intravenous (IV) infusion for patients who cannot tolerate oral administration or require rapid control. Tablets are available in strengths such as 100 mg and 300 mg, while the IV form is a 500 mg/vial powder.


Dosing and Frequency Patterns

The treatment pattern for chronic hyperuricemia, such as gout, involves a titrated dosing schedule. The standard starting dose for adults with normal renal function is 100 mg once daily. The dose is subsequently increased in 100 mg increments at weekly intervals until the target serum urate concentration is reached. The maximum recommended daily dose for adults is 800 mg. Total daily doses exceeding 300 mg may be taken in divided doses.

For hyperuricemia associated with cancer therapy (Tumor Lysis Syndrome prophylaxis), use is typically short-term, starting one to two days before cytotoxic treatment. IV administration uses a daily dose of 200 to 400 mg/m^2, administered as a single infusion or divided into equally split infusions over 6, 8, or 12-hour intervals.


Administration Conditions and Adjustments

Oral tablets are generally instructed to be taken after meals to help minimize potential stomach upset. Maintaining adequate fluid intake is also recommended. Dosage adjustments are required for patients with impaired renal function; for example, a maximum dose of 100 mg/day is often recommended for severe impairment (CrCl < 10 mL/min). The IV solution requires specialized reconstitution and dilution to a maximum concentration of 6 mg/mL and must be administered within ten hours of preparation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Progout (Allopurinol)

Evidence for Use in Chronic Hyperuricemia and Gout

Randomized Controlled Trials (RCTs) and other research designs have explored Progout in contexts involving high uric acid levels and gout. These studies were applied in populations of adult patients with established gout. Researchers monitored changes in physiological markers, particularly the achievement and maintenance of specific target serum uric acid (sUA) concentrations.

Studies also examined clinical outcomes related to physical discomfort, such as how often patients experienced gout attacks or flares during the study period. Longer observational studies monitored changes in the size or presence of tophi (urate deposits). Data show patterns related to measurements of sUA levels over time in the observed populations. Furthermore, some research describes changes related to the incidence of gout flares over time, and observational studies describe changes in the size of tophi over extended periods in some individuals.

Evidence for Use in Tumor Lysis Syndrome (TLS) Prophylaxis

Research has explored Progout in specific high-risk research scenarios related to Tumor Lysis Syndrome (TLS) prophylaxis. This research utilized comparative studies and data from regulatory submissions, focusing on both adult and pediatric patients with certain cancers being studied for rapid cytotoxic therapy. The primary research focus was on monitoring the medicine when studying a sudden, significant increase in serum uric acid that often occurs when cancer cells rapidly break down.

Studies monitored physiological strain related to this acute event, examining measures such as the prevention of acute kidney injury. Data show patterns related to the medicine's influence on the acute urate spike during the critical short-term period surrounding high-dose treatment. This evidence contributes to understanding the rapid symptom patterns associated with temporary physiological imbalance. However, the available research generally focuses on the immediate, short-term outcomes during the week of high-risk treatment.

Key Studies & References

  1. Clinical Practice Guidelines for the Management of Tumor Lysis Syndrome (Pediatric/Adult Management)
  2. Tumor Lysis Syndrome (TLS) in Adult Patients - MD Anderson Cancer Center Clinical Algorithm (TLS Prophylaxis)

Frequently Asked Questions (FAQ)

Common questions about Progout (FAQ)

Q: How quickly does Progout usually start to show an effect?

A: Progout begins to affect your body's chemistry and reduce uric acid production within the first 2 to 3 days. However, official studies indicate that it typically takes about 1 to 2 weeks of continuous use to reach the full, steady reduction of uric acid levels in the blood.

Q: Does Progout cure the condition, or does it only manage symptoms?

A: Official information describes Progout as a medicine for long-term management of chronic conditions, such as high uric acid levels. It functions as a foundational medicine that modifies the underlying disease process by controlling uric acid production, but it is not described as a cure.

Q: Do I need to take Progout forever?

A: For chronic conditions like gout, Progout is often prescribed as a lifelong treatment to keep uric acid levels controlled over time. Discontinuation carries an officially recognized risk of symptom recurrence.

Q: What happens if I miss taking Progout sometimes?

A: If a dose is missed, regulatory guidance generally states it is taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose is usually skipped. Regulatory guidance advises against taking two doses at the same time to make up for a missed one.

Q: Can Progout affect my sleep?

A: Some official safety information lists effects on the central nervous system, such as drowsiness and sedation, as documented adverse reactions. Safety warnings indicate caution may be required for activities that demand full mental alertness until the medicine's effect is known.

Q: What are the signs that Progout is working?

A: The primary way Progout is intended to work is by consistently lowering and maintaining uric acid levels in the blood below a target amount. Over an extended period, successful treatment is studied to potentially lead to fewer gout attacks and a decrease in the size of urate deposits, known as tophi.

Q: Are there any known interactions between Progout and alcohol?

A: Official safety information notes that consuming alcohol may increase the nervous system side effects of Progout, such as dizziness or feeling drowsy. The safety profile advises caution regarding alcohol use.

Q: Can I take Progout if I have a history of stomach problems?

A: Nausea and diarrhea are documented as common adverse effects of Progout. The official instructions state the tablets are taken after a meal to help reduce the possibility of stomach irritation. Regulatory labeling indicates that dosage adjustments or special precautions are required for those with pre-existing liver or kidney conditions.

Q: What happens when I stop taking Progout?

A: Official guidance warns that stopping Progout suddenly carries a high risk that the underlying condition may get worse, potentially resulting in a painful gout flare. Stopping the medicine should not be done on one’s own.

Q: Is Progout recommended for pregnant or breastfeeding people?

A: Progout is generally not recommended during pregnancy or while breastfeeding unless a healthcare provider determines the use is absolutely necessary. The medicine's active substance can be present in breast milk, according to regulatory documents.

Q: Is Progout used for other conditions besides what it's mainly prescribed for?

A: Yes, regulatory documents approve Progout for uses beyond chronic high uric acid levels and gout. These uses include treating certain recurrent kidney stones and preventing high uric acid buildup in the blood (prophylaxis) for patients receiving specific cancer treatments.

Q: What's the difference between Progout and other common medications for this condition?

A: Progout is classified as a Xanthine Oxidase Inhibitor (XOI), meaning its action is to block an enzyme and reduce the production of uric acid. This mechanism differs from other medicines that treat the same condition, which may work by helping the kidneys increase the excretion of uric acid through urine.

Q: Is it common to feel a little dizzy when first starting Progout?

A: Dizziness and headaches are documented as potential side effects associated with the use of Progout. Because of the risk of these effects, safety warnings indicate caution may be required for activities that demand full mental alertness.

Q: Are there any specific foods or drinks to avoid while taking Progout?

A: Regulatory documents indicate that there are no specific foods or drinks that must be entirely avoided. The regulatory instructions state the medicine is usually taken after a meal to help tolerance, and that maintaining adequate fluid intake is advised. It must also be separated from the antacid Aluminum Hydroxide.

Q: Does Progout interact with vitamins or supplements like Vitamin D or magnesium?

A: Official regulatory warnings primarily list interactions with other prescription medicines. While some studies have examined Progout's effect on nutrient levels like Vitamin D, there are no specific warnings for a direct negative interaction with general vitamin or mineral supplements detailed in the core regulatory labels.

Q: Will I need regular blood tests while I am taking Progout?

A: Yes, official regulatory documents indicate that regular blood tests are often required while taking Progout. These tests are used to check the drug's effectiveness by monitoring your uric acid levels and to monitor safety indicators related to liver enzyme levels and kidney function.

Q: What research is currently being done on Progout?

A: Current research on Progout is being explored in clinical trial settings, often detailed on government registries like those maintained by the NIH. These trials are designed to evaluate the medicine's use in specific patient populations, such as those with certain cancer or blood disorders.

Q: Are there different strengths or forms of Progout?

A: Yes, official product information confirms that Progout is available in different strengths and forms. These commonly include oral tablets (such as 100 mg, 200 mg, and 300 mg) and a powder for intravenous injection (IV) that is used in hospital or specialized settings.

Q: Is there a generic version of Progout available?

A: Yes, the active ingredient in Progout, Allopurinol, is available as an FDA-approved generic version. Regulatory information confirms that generic formulations are approved because they are shown to be bioequivalent (work the same way) as the branded product.

Q: Is it normal to have mild headaches when starting this drug?

A: Headaches are a documented potential side effect associated with the use of Progout. As with any persistent or severe symptom, official guidance advises communication with a healthcare professional.

Q: Does Progout interact with birth control pills?

A: Progout is not typically listed as a medicine that significantly changes the metabolism of hormonal birth control. However, specific information regarding its interaction with hormonal contraceptives is not universally detailed across all regulatory labels.

Q: Does Progout affect mood or cause depression?

A: Official safety documentation notes certain effects on the central nervous system (CNS) and behavioral changes as rare adverse events. However, mood changes or depression are not listed as common or required adverse effects in the core regulatory labels.

Q: Is there a link between Progout and hair loss?

A: Some regulatory documents note that alopecia (hair loss) has been reported in rare cases as a potential adverse reaction. It is listed as one of the less common effects observed during post-market surveillance.

Q: Are there any known interactions with herbal teas or remedies?

A: Official drug interaction lists focus on prescription and over-the-counter medicines. Regulatory bodies generally provide caution regarding the concurrent use of herbal products or remedies, as detailed interaction information is not always present in regulatory labeling.

Q: What is the shelf life of Progout?

A: When stored correctly according to official instructions, the typical shelf life for Progout tablets is stated in manufacturing documentation as 36 months (3 years) from the date of manufacture. The medicine should never be used past the expiration date printed on the package.

How should Progout be stored and disposed of?

How to Store and Dispose of Progout (Allopurinol)

Progout (allopurinol) tablets must be stored at room temperature, typically below 25 C (77 F). The medicine must be kept in its original container with the lid tightly closed to protect it from moisture and excessive heat; do not freeze the tablets. For safety, Progout must be stored out of the sight and reach of children.

Do not use the medicine after the expiration date on the package. Unused or expired tablets should be disposed of via a drug take-back program. If a take-back program is unavailable, mix the tablets with an undesirable substance before disposal in the household trash. The medicine must not be flushed down the toilet or disposed of into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Progout found in:

A-Z Index: